Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Influenza Prophylaxis Clear all

Conditions: Influenza
Interventions: CD388 Injection, Placebo; Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 63 Years
Enrollment: 5,071 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 56
States / cities: Anniston, Alabama • Cullman, Alabama • Tempe, Arizona + 51 more

Conditions: Seasonal Influenza
Interventions: VXA-A1.1; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Childhood Influenza Vaccination, School-located Influenza Vaccination
Interventions: Text message notification; Other
Lead sponsor: University of Rochester; Other
Eligibility: 4 Years to 19 Years
Enrollment: 18,540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Plasma Cell Neoplasm
Interventions: Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions: Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 65 Years and older
Enrollment: 777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more

Conditions: Healthy
Interventions: INO-3605, INO-3609, INO-3401, INO-3605 AND INO-3609, INO-3510, Seasonal Influenza vaccine; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Overland Park, Kansas • Baltimore, Maryland

Conditions: Influenza, Healthy
Interventions: Trivalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: South Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Influenza, Healthy
Interventions: Trivalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Influenza Vaccination
Interventions: Fact Only Education Message, Fact and Myth Educational Message, Fact, Myth, Why Educational Message, Control Educational Message; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Influenza
Interventions: Oseltamivir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • Palo Alto, California • Bethesda, Maryland + 1 more

Conditions: COVID-19 Prevention
Interventions: Ad26.COV2.S, Placebo, Influenza Vaccine; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 861 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more

Conditions: Influenza, Healthy
Interventions: FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018); Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 24 Months to 47 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 12
States / cities: Savannah, Georgia • Bardstown, Kentucky • St Louis, Missouri + 9 more

Conditions: Influenza, COVID-19
Interventions: Provider communication training; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 24,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Influenza, Healthy Volunteers
Interventions: Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 581 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more

Conditions: Influenza
Interventions: Influenza; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,847 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 15
States / cities: Clearwater, Florida • Evansville, Indiana • Baltimore, Maryland + 12 more

Conditions: Avian Influenza
Interventions: ND1.1; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Influenza
Interventions: Trivalent influenza virus vaccine, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Daytona Beach, Florida • Portland, Oregon • Austin, Texas

Conditions: Prophylaxis: Influenza
Interventions: TIVc_LOT A, TIVc_LOT B, TIVc_LOT C, TIVf; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,561 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 24
States / cities: Anaheim, California • Redding, California • San Diego, California + 19 more

Conditions: Influenza, Healthy
Interventions: Monovalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 3
States / cities: South Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Influenza
Interventions: Influenzae vaccine; Drug
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Healthy
Interventions: HAI-05 Influenza Vaccine, Saline; Biological · Other
Lead sponsor: Fraunhofer, Center for Molecular Biotechnology; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Wichita, Kansas • Kansas City, Missouri

Conditions: Immunizations, Vaccination, Influenza, School Health
Interventions: School based flu vaccine: Low intensity, School based flu vaccine: High intensity; Behavioral
Lead sponsor: Monroe County Department of Public Health; Other
Eligibility: 4 Years to 13 Years
Enrollment: 25,366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy Participants
Interventions: Influenza virus vaccine, Vitamins A and D, Placebo; Biological · Dietary Supplement · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 8 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum

Evaluation of the School Kids Influenza Prevention Project

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination

Alternative Oseltamivir Dosing Strategies

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

Patient-Centered Practical Vaccine Talk For Busy Clinicians

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine

Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season

Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children